{"id":798937,"date":"2025-01-08T08:37:13","date_gmt":"2025-01-08T13:37:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"modified":"2025-01-08T08:37:13","modified_gmt":"2025-01-08T13:37:13","slug":"crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ZUG, Switzerland and BOSTON, Jan.  08, 2025  (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco.<\/p>\n<p align=\"justify\">A live webcast of the fireside chat will be available on the &#8220;Events &amp; Presentations&#8221; page in the Investors section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZIPXZfjW5twH_9zlakTvBhSZbkCMnfnkf_wEqG10tu4i2AGUpMCWJDuT6anY6zJRn_bzhRdmDHxT4GX6NnpSd9LGHbEA4HByV-4UZ7_WSmdYVSTJbfMqtAUi5u9IKehz\" rel=\"nofollow\" target=\"_blank\">https:\/\/crisprtx.gcs-web.com\/events<\/a>. A replay of the webcast will be archived on the Company&#8217;s website for 14 days following the presentation.<\/p>\n<p>\n        <strong>About CRISPR Therapeutics<\/strong><br \/>\n        <br \/>Since its inception over a decade ago,\u00a0CRISPR Therapeutics\u00a0has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases.\u00a0CRISPR Therapeutics\u00a0advanced the first-ever CRISPR\/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY\u2122 (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts,\u00a0CRISPR Therapeutics\u00a0has established strategic partnerships with leading companies including\u00a0Bayer\u00a0and Vertex Pharmaceuticals.\u00a0CRISPR Therapeutics AG\u00a0is headquartered in\u00a0Zug, Switzerland, with its wholly-owned\u00a0U.S.\u00a0subsidiary,\u00a0CRISPR Therapeutics, Inc., and R&amp;D operations based in\u00a0Boston, Massachusetts\u00a0and\u00a0San Francisco, California, and business offices in\u00a0London, United Kingdom. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Zt_RQXJ4cf8V_sY5m8WRKyliPccbaS2XjJkJhxqXc1gvzqFTvEwgzunQ59GLb-pnkthhLIm86P3NssXRPaRUfRNmhffJEJhAaaTyH3b-usgSSWx1BWAkUQTqyWkjt2cm4xCBROiaai6X7bc0idD74FMwlSlQW8BqoNFIQ-RdXmompIhkkgjftYIJ2Fs9XF1qOQ8Reeu_0bFHKL0Ci2SJTM5bRxXFCaaulo-ZbNxwzjyt_fUrHj6HVClQDBnga83CeZ4q_wcWQNEtPsbtldqT0MbU3kk--UsudaqyU3v3zF2zZxp3sIpqcSXNyjEbQVH0OKYLBTcOx-5SSgaVn9iz4GH_oRJdMH8VxNI_bK6rYjn-mhXKetmjb3ks-yotEwOe1PJLOwEuiKdXe-D1I2x8dfKQjFAPRgvfJWMgFrSCwjOoQyadweYr2-y47gKIUVQ242ys7dnfmd-grsn2yo3LjYVxLOlbISZgJ3KQVpyo_82f-kqXbUgO7pkdfMIQ7SqGoF6Bpgxng-esoe_Tfo2IIHfX0JmTAmmoPOl2MXhCfPw11CdNITBfAT98Uo99sNEOcr_upHwyjnpgNqhxBtGBVtUhrndCN9P2xipglZ5uiHULWU-NB_p4XOXiNmLRXL5QhsF83AnQu8TXgNgL8eTczL3fCFW4oWJVbAlR9JpdTGM=\" rel=\"nofollow\" target=\"_blank\">www.crisprtx.com<\/a>.\u00a0<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Susan Kim<br \/>+1-617-307-7503<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zIwO8e1rqhv6Ol_A_MgsCm_VDbl3Tw10iQipptHG2aElQWh_hMRIr9GHsp4it2Mbt3xfLpauxg5qL9rY3-vGGaAYOGoZzZmtBAcs8YTJiBc=\" rel=\"nofollow\" target=\"_blank\">susan.kim@crisprtx.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Rachel Eides<br \/> +1-617-315-4493<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A_siKMD7ulta_0SmH0jeAeu16h41PUhN3ezOioyhplONRwcdGN1JKjt03IxizmzjTkxEXpV4uk7XbvEyO75IPk4jPnNA__WczgE70MHEjx3tUPcGkq8Yktf7kPMYkHQ0\" rel=\"nofollow\" target=\"_blank\">rachel.eides@crisprtx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDdiMjBlZDctZDBlMi00OTljLTgyZWUtMzljY2I2NmVkNTBiLTEwNjE0ODI=\/tiny\/CRISPR-Therapeutics-AG.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the &#8220;Events &amp; Presentations&#8221; page in the Investors section of the Company&#8217;s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company&#8217;s website for 14 days following the presentation. About CRISPR Therapeutics Since its inception over a decade ago,\u00a0CRISPR Therapeutics\u00a0has transformed from a research-stage company advancing programs in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798937","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the &#8220;Events &amp; Presentations&#8221; page in the Investors section of the Company&#8217;s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company&#8217;s website for 14 days following the presentation. About CRISPR Therapeutics Since its inception over a decade ago,\u00a0CRISPR Therapeutics\u00a0has transformed from a research-stage company advancing programs in &hellip; Continue reading &quot;CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T13:37:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2025-01-08T13:37:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":340,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=\",\"datePublished\":\"2025-01-08T13:37:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the &#8220;Events &amp; Presentations&#8221; page in the Investors section of the Company&#8217;s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company&#8217;s website for 14 days following the presentation. About CRISPR Therapeutics Since its inception over a decade ago,\u00a0CRISPR Therapeutics\u00a0has transformed from a research-stage company advancing programs in &hellip; Continue reading \"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-08T13:37:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference","datePublished":"2025-01-08T13:37:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"wordCount":340,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","name":"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=","datePublished":"2025-01-08T13:37:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODYxMyM2NjgzMTk1IzIwNDk5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798937"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798937\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}